MedPath

OCS™ Lung TOP Registry For Donor Lungs for Transplantation

Active, not recruiting
Conditions
Lung Transplantation
Interventions
Device: OCS Lung System
Registration Number
NCT03639025
Lead Sponsor
TransMedics
Brief Summary

Single-arm, prospective, multi-center, post-approval U.S. registry

Detailed Description

This is an all-comers registry that will enroll:

1. Patients who receive OCS™ preserved double lung transplants from either standard criteria donors or donors initially deemed unacceptable; and

2. Patients who receive a single lung transplant from OCS™ preserved lung pairs from either standard criteria donors or donors initially deemed unacceptable; and

3. All donor lungs that were perfused on OCS Lung System.

Enrolled patients will fall into one of the following three possible analysis categories:

1. TOP SCDL PAS Primary Analysis Population: will be comprised of recipients transplanted with SCDL primary analysis population eligible donor lungs preserved on the OCS™ Lung System.

2. TOP DLIDU Primary Analysis Population: Will be comprised of recipients transplanted with DLIDU primary analysis population eligible donor lungs preserved on the OCS™ Lung System.

3. All Other Enrolled Patients: will be comprised of all OCS Lung transplanted patients in the TOP Registry that do not meet any of the above analysis populations.

Patient enrollment in the TOP Registry will continue until 266 eligible DLIDU Primary Analysis Population recipients have been enrolled.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
458
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Standard Donor Lungs Primary Analysis PopulationOCS Lung SystemRecipients transplanted with primary analysis population eligible donor lungs preserved on the OCS™ Lung System.
All Other Enrolled PatientsOCS Lung SystemAll OCS Lung transplanted patients that do not meet any of the above analysis populations.
Donor Lungs Initially Unacceptable Primary Analysis Pop.OCS Lung SystemRecipients transplanted with primary analysis population eligible donor lungs preserved on the OCS™ Lung System.
Primary Outcome Measures
NameTimeMethod
12-month patient and graft survival post double-lung transplant12 months

Primary Effectiveness Endpoint

Secondary Outcome Measures
NameTimeMethod
Donor Lungs Initially Deemed Unacceptable - Incidence of PGD3 at 72 hours post-transplantation72 hours

Primary Graft Dysfunction

Standard Criteria Donor Lungs - Total ischemic time for OCS™-preserved lungs2 hours

Lung ischemic time

Donor Lungs Initially Deemed Unacceptable - Incidence of PGD3 within the initial 72 hours post-transplantationWithin 72 hours post-transplantation

Primary Graft Dysfunction

Standard Criteria Lungs - Incidence of Primary Graft Dysfunction (PGD) grade 3 within the initial 72 hours post-transplantation (T0, T24, T48, and T72 hours)0, 24, 48 and 72 hours

Primary Graft Dysfunction

Donor Lungs Initially Deemed Unacceptable - Donor Lung Utilization Rate1 hour

Utilization Rate

Trial Locations

Locations (18)

Houston Methodist

🇺🇸

Houston, Texas, United States

Medical College of Wisconsin

🇺🇸

Milwaukee, Wisconsin, United States

St. Joseph's Hospital and Medical Center

🇺🇸

Phoenix, Arizona, United States

UCLA

🇺🇸

Los Angeles, California, United States

Stanford University

🇺🇸

Palo Alto, California, United States

UCSF

🇺🇸

San Francisco, California, United States

Tampa General Hospital

🇺🇸

Tampa, Florida, United States

Emory

🇺🇸

Atlanta, Georgia, United States

University of Chicago

🇺🇸

Chicago, Illinois, United States

Johns Hopkins

🇺🇸

Baltimore, Maryland, United States

Massachusetts General Hospital

🇺🇸

Boston, Massachusetts, United States

Henry Ford Health System

🇺🇸

Detroit, Michigan, United States

University of Minnesota

🇺🇸

Minneapolis, Minnesota, United States

Nebraska Medical Center

🇺🇸

Omaha, Nebraska, United States

Duke University

🇺🇸

Durham, North Carolina, United States

Temple University

🇺🇸

Philadelphia, Pennsylvania, United States

Baylor Scott & White Research Institute

🇺🇸

Dallas, Texas, United States

Baylor St. Luke's Medical Center

🇺🇸

Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath